{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:26:14Z","timestamp":1757618774474,"version":"3.44.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40256-025-00749-6","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T17:05:25Z","timestamp":1752339925000},"page":"715-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9125-0190","authenticated-orcid":false,"given":"Bart P. H.","family":"Slob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike","family":"Weersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4356-8566","authenticated-orcid":false,"given":"Hans-Peter Brunner-La","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-0670","authenticated-orcid":false,"given":"Lisa A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-2638","authenticated-orcid":false,"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/jcm5070062","volume":"5","author":"AA Inamdar","year":"2016","unstructured":"Inamdar AA, Inamdar AC. Heart failure: diagnosis, management and utilization. J Clin Med. 2016;5:62.","journal-title":"J Clin Med"},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/bmj.320.7229.236","volume":"320","author":"RDS Watson","year":"2000","unstructured":"Watson RDS, Gibbs CR, Lip GYH. ABC of heart failure: clinical features and complications. BMJ. 2000;320:236\u20139.","journal-title":"BMJ"},{"key":"749_CR3","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118:3272\u201387.","journal-title":"Cardiovasc Res"},{"key":"749_CR4","unstructured":"Dutch Heart Association. Heart failure statistics. [cited 2024 Mar 21]. https:\/\/www.hartenvaatcijfers.nl\/jaarcijfers\/jaarcijfers-hartfalen-40b27."},{"key":"749_CR5","unstructured":"RIVM. Hartfalen | Zorguitgaven | Volksgezondheid en Zorg. [cited 2024 Jan 23]. https:\/\/www.vzinfo.nl\/hartfalen\/zorguitgaven."},{"issue":"21","key":"749_CR6","first-page":"00050","volume":"S1071\u20139164","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the heart failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021;S1071\u20139164(21):00050\u20136.","journal-title":"J Card Fail"},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10741-024-10385-y","volume":"29","author":"N Desai","year":"2024","unstructured":"Desai N, Olewinska E, Famulska A, Remuzat C, Francois C, Folkerts K. Heart failure with mildly reduced and preserved ejection fraction: a review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Fail Rev. 2024;29:631\u201362.","journal-title":"Heart Fail Rev"},{"key":"749_CR8","unstructured":"European Society of Cardiology. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. [cited 2024 Feb 15]. https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Focused-Update-on-Heart-Failure-Guidelines, https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Focused-Update-on-Heart-Failure-Guidelines."},{"key":"749_CR9","unstructured":"American Heart Association. Classes and stages of heart failure. www.heart.org. [cited 2024 Feb 15]. https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/classes-of-heart-failure."},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"749_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148\u201358.","journal-title":"JAMA Cardiol."},{"key":"749_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372: m4573.","journal-title":"BMJ"},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","volume":"23","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23:3651.","journal-title":"Int J Mol Sci"},{"key":"749_CR14","unstructured":"Zorginstituut Nederland. SGLT2-remmers. Zorginstituut Nederland; [cited 2024 Jan 23]. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/groepsteksten\/sglt2_remmers."},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","volume":"18","author":"S Pabel","year":"2021","unstructured":"Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 inhibitors and their mode of action in heart failure\u2014has the mystery been unravelled? Curr Heart Fail Rep. 2021;18:315\u201328.","journal-title":"Curr Heart Fail Rep"},{"key":"749_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"749_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JV McMurray John","year":"2019","unstructured":"McMurray John JV, Solomon Scott D, Inzucchi Silvio E, Lars K, Kosiborod Mikhail N, Martinez Felipe A, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"749_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"749_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"D Solomon Scott","year":"2022","unstructured":"Solomon Scott D, McMurray John JV, Brian C, de Boer Rudolf A, David D, Hernandez Adrian F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398.","journal-title":"N Engl J Med"},{"key":"749_CR20","unstructured":"EMA. European Commission approves SGLT2i in chronic HF regardless of ejection fraction. [cited 2024 Jan 22]. https:\/\/pace-cme.org\/news\/european-commission-approves-sglt2i-in-chronic-hf-regardless-of-ejection-fraction\/2456159\/."},{"key":"749_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/ph15010047","volume":"15","author":"K Kowalska","year":"2021","unstructured":"Kowalska K, Walczak J, Femlak J, M\u0142ynarska E, Franczyk B, Rysz J. Empagliflozin\u2014a new chance for patients with chronic heart failure. Pharmaceuticals. 2021;15:47.","journal-title":"Pharmaceuticals"},{"key":"749_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jjcc.2023.02.007","volume":"81","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Sakamaki H, Momomura S, Sakata Y, Kotobuki Y, Linden S, et al. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial. J Cardiol. 2023;81:522\u201330.","journal-title":"J Cardiol"},{"key":"749_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008638","volume":"15","author":"J Zhou","year":"2022","unstructured":"Zhou J, Liew D, Kaye DM, Zoungas S, Stub D. Cost-effectiveness of empagliflozin in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Qual Outcomes. 2022;15: e008638.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"749_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029042","volume":"13","author":"OS Reifsnider","year":"2024","unstructured":"Reifsnider OS, Tafazzoli A, Linden S, Ishak J, Rakonczai P, Stargardter M, et al. Cost-effectiveness analysis of empagliflozin for treatment of patients with heart failure with reduced ejection fraction in the United States. J Am Heart Assoc. 2024;13: e029042.","journal-title":"J Am Heart Assoc"},{"key":"749_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CEOR.S391455","volume":"15","author":"T Hallinen","year":"2023","unstructured":"Hallinen T, Kivel\u00e4 S, Soini E, Harjola V-P, Pesonen M. Cost-effectiveness of empagliflozin in combination with standard care versus standard care only in the treatment of heart failure patients in Finland. Clin Outcomes Res. 2023;15:1\u201313.","journal-title":"Clin Outcomes Res."},{"key":"749_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2459\/JCM.0000000000001532","volume":"24","author":"S Kolovos","year":"2023","unstructured":"Kolovos S, Bellanca L, Groyer H, Rosano G, Gaultney J, Linden S. Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England. J Cardiovasc Med Hagerstown Md. 2023;24:758\u201364.","journal-title":"J Cardiovasc Med Hagerstown Md."},{"key":"749_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187477","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van RL. Update of the Dutch manual for costing studies in health care. PLoS ONE. 2017;12: e0187477.","journal-title":"PLoS ONE"},{"key":"749_CR28","unstructured":"Zorginstituut Nederland. Guideline manual for perfoming economic evaluations in healthcare (Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg). Ministerie van Volksgezondheid, Welzijn en Sport; 2016 [cited 2023 Dec 1]. https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg."},{"key":"749_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health J Int Soc Pharmacoecon Outcomes Res. 2022;25:3\u20139.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res."},{"key":"749_CR30","unstructured":"Zorginstituut Nederland. Dutch reimbursement dossier of empagliflozin for the treatment of heart failure. Ministerie van Volksgezondheid, Welzijn en Sport; 2023 [cited 2024 Sep 3]. https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2023\/01\/31\/gvs-advies-empagliflozine-jardiance."},{"key":"749_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33:743\u201354.","journal-title":"Med Decis Mak"},{"key":"749_CR32","unstructured":"G-Standaard\u2014Z-Index. [cited 2024 Mar 1]. https:\/\/www.z-index.nl\/g-standaard"},{"key":"749_CR33","unstructured":"Nederland Z. GIPdatabank.nl. Zorginstituut Nederland; [cited 2024 Mar 1]. https:\/\/www.gipdatabank.nl\/."},{"key":"749_CR34","unstructured":"Zorginstituut Nederland W en S. Dutch reimbursement dossier of dapagliflozin for the treatment of heart failure. Ministerie van Volksgezondheid, Welzijn en Sport; 2021 [cited 2024 Apr 22]. https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2021\/05\/12\/gvs-advies-uitbreiding-bijlage-2-voorwaarden-voor-dapagliflozine-forxiga"},{"key":"749_CR35","unstructured":"Centraal bureau voor de statistiek. Consumentenprijzen; prijsindex 2015=100. Cent. Bur. Voor Stat. 2024 [cited 2024 Jan 23]. https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/83131ned."},{"key":"749_CR36","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jval.2016.05.018","volume":"19","author":"PW Sullivan","year":"2016","unstructured":"Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Health J Int Soc Pharmacoecon Outcomes Res. 2016;19:1002\u20138.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res."},{"key":"749_CR37","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/0272989X16658660","volume":"36","author":"T Peasgood","year":"2016","unstructured":"Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Mak Int J Soc Med Decis Mak. 2016;36:1020\u201333.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak."},{"key":"749_CR38","unstructured":"Zorginstituut Nederland. Kosteneffectiviteit in de praktijk. Ministerie van Volksgezondheid, Welzijn en Sport; 2015 [cited 2024 Mar 1]. https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2015\/06\/26\/kosteneffectiviteit-in-de-praktijk"},{"key":"749_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","volume":"7","author":"H-P Brunner-La Rocca","year":"2019","unstructured":"Brunner-La Rocca H-P, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma H-J, Westendorp PH, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry. JACC Heart Fail. 2019;7:13\u201321.","journal-title":"JACC Heart Fail."},{"key":"749_CR40","first-page":"370","volume":"29","author":"A Uijl","year":"2021","unstructured":"Uijl A, Veenis JF, Brunner-La Rocca HP, van Empel V, Linssen GCM, Asselbergs FW, et al. Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry. Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found. 2021;29:370\u20136.","journal-title":"Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found."},{"key":"749_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","volume":"29","author":"PHM van Baal","year":"2011","unstructured":"van Baal PHM, Wong A, Slobbe LCJ, Polder JJ, Brouwer WBF, de Wit GA. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics. 2011;29:175\u201387.","journal-title":"Pharmacoeconomics"},{"key":"749_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, et al. Value of information analysis for research decisions\u2014an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23:139\u201350.","journal-title":"Value Health."},{"key":"749_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.683281","volume":"8","author":"D Pan","year":"2021","unstructured":"Pan D, Xu L, Chen P, Jiang H, Shi D, Guo M. Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2021;8: 683281.","journal-title":"Front Cardiovasc Med."},{"key":"749_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/ehf2.15088","volume":"12","author":"M Amioka","year":"2025","unstructured":"Amioka M, Kinoshita H, Fuji Y, Nitta K, Yamane K, Shokawa T, et al. Long-term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS-HF study. ESC Heart Fail. 2025;12:447\u201355.","journal-title":"ESC Heart Fail."},{"key":"749_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3197","author":"JA Davis","year":"2024","unstructured":"Davis JA, Booth D, McEwan P, Solomon SD, McMurray JJV, de Boer RA, et al. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: a pooled analysis of DAPA-HF and DELIVER data. Eur J Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ejhf.3197.","journal-title":"Eur J Heart Fail"},{"key":"749_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cardfail.2016.12.002","volume":"23","author":"N Hawwa","year":"2017","unstructured":"Hawwa N, Vest AR, Kumar R, Lahoud R, Young JB, Wu Y, et al. Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in assessing functional capacity and clinical outcomes. J Card Fail. 2017;23:280\u20135.","journal-title":"J Card Fail"},{"key":"749_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1186579\/full","author":"J Liu","year":"2023","unstructured":"Liu J, Liu D, Gong X, You R. Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1186579\/full.","journal-title":"Front Pharmacol"},{"key":"749_CR48","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ejhf.1978","volume":"22","author":"P McEwan","year":"2020","unstructured":"McEwan P, Darlington O, McMurray JJV, Jhund PS, Docherty KF, B\u00f6hm M, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020;22:2147\u201356.","journal-title":"Eur J Heart Fail"},{"key":"749_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07515-3","author":"L Lin","year":"2023","unstructured":"Lin L, Xiu Q, Liu F, Zhang H, Chen Y. Cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: the DELIVER trial. Cardiovasc Drugs Ther. 2023. https:\/\/doi.org\/10.1007\/s10557-023-07515-3.","journal-title":"Cardiovasc Drugs Ther"},{"key":"749_CR50","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/ejhf.2940","volume":"25","author":"D Booth","year":"2023","unstructured":"Booth D, Davis JA, McEwan P, Solomon SD, McMurray JJV, De Boer RA, et al. The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health-economic analysis of the DELIVER trial. Eur J Heart Fail. 2023;25:1386\u201395.","journal-title":"Eur J Heart Fail"},{"key":"749_CR51","unstructured":"Hartstichting. Actuele cijfers hart- en vaatziekten. Hartstichting. 2023 [cited 2025 Jun 5]. https:\/\/www.hartstichting.nl\/hart-en-vaatziekten\/cijfers-hart-en-vaatziekten."},{"key":"749_CR52","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1093\/eurheartj\/ehaf244","volume":"46","author":"J Malgie","year":"2025","unstructured":"Malgie J, Wilde MI, Brunner-La Rocca H-P, Emans ME, De Boer GA, Siegers CEP, et al. Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy. Eur Heart J. 2025;46:2394\u2013405.","journal-title":"Eur Heart J"},{"key":"749_CR53","unstructured":"Centraal bureau voor de statistiek. StatLine\u2014labor participation in the Netherlands. [cited 2024 Apr 22]. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/85264NED\/table?dl=9F1C6."},{"key":"749_CR54","doi-asserted-by":"publisher","first-page":"851","DOI":"10.7326\/M21-4284","volume":"175","author":"X Zou","year":"2022","unstructured":"Zou X, Shi Q, Vandvik PO, Guyatt G, Lang CC, Parpia S, et al. Sodium-glucose cotransporter-2 inhibitors in patients with heart failure\u202f: a systematic review and meta-analysis. Ann Intern Med. 2022;175:851\u201361.","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00749-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00749-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00749-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T06:31:30Z","timestamp":1757226690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00749-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00749-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"29 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Boehringer Ingelheim Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Cornelis Boersma and Maarten Postma receive grants and honoraria from various pharmaceutical companies, including Boehringer Ingelheim. They are both shareholders of Health-Ecore, the Netherlands, which received a consultancy fee for the conduct of this study. Bart Slob and Lisa de Jong are employees at Health-Ecore. Maaike Weersma is an employee at Boehringer Ingelheim Netherlands, the funder of this study. Hans-Peter Brunner-La Rocca has received consultancy fees from Boehringer-Ingelheim, unrelated to this publication. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All relevant data are included in the article. The analyses were conducted based on publicly available information, which is presented and referenced in the article and its supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Methodology: BS, LdJ. Formal analysis and investigation: BS, LdJ. Visualization: BS. Validation: LdJ. Writing \u2013 original draft preparation: BS. Writing \u2013 review and editing: LdJ, HPBLR, MP, CB. Supervision: MP, CB. Project administration: MW.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}